AURA Stock Price, Aura Biosciences, Inc. Quote, Chart

Market Summary

USD7.22+0.14

Market Closed

1.98%

AURA Stock Price

View Fullscreen

AURA RSI Chart

AURA Valuation

Market Cap

357.4M

Price/Earnings (Trailing)

-4.68

EV/EBITDA

-4.22

Price/Free Cashflow

-5.54

MarketCap/EBT

-4.69

AURA Price/Earnings (Trailing)

AURA Profitability

Return on Equity

-33.83%

Return on Assets

-29.96%

Free Cashflow Yield

-18.06%

AURA Fundamentals

AURA Earnings

Earnings (TTM)

-76.4M

Earnings Growth (Yr)

-33.65%

Earnings Growth (Qtr)

-19.55%

Breaking Down AURA Revenue

Last 7 days

0.4%

Last 30 days

-6.2%

Last 90 days

-4.9%

Trailing 12 Months

-21.3%

How does AURA drawdown profile look like?

AURA Financial Health

Current Ratio

18.76

AURA Investor Care

Shares Dilution (1Y)

30.96%

Diluted EPS (TTM)

-1.93

Tracking the Latest Insider Buys and Sells of Aura Biosciences, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 02, 2024	kilroy conor	acquired	-	-	96,000	general counsel and secretary
Feb 01, 2024	feder julie b	acquired	-	-	71,285	chief financial officer
Feb 01, 2024	de los pinos elisabet	acquired	-	-	162,935	see remarks
Feb 01, 2024	hopkins janet jill	acquired	-	-	28,515	chief medical officer
Jan 23, 2024	de los pinos elisabet	sold	-121,141	7.6415	-15,853	see remarks
Jan 23, 2024	feder julie b	sold	-50,521	7.6443	-6,609	chief financial officer
Nov 09, 2023	matrix capital management company, lp	bought	14,040,000	9.00	1,560,000	-
Nov 08, 2023	johnson david michael	bought	73,000	7.3	10,000	-
Nov 08, 2023	johnson david michael	bought	70,087	7.3	9,601	-

Which funds bought or sold AURA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Bank of New York Mellon Corp	added	4.64	-58,275	741,651	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-42.4	-9,000	10,000	-%
Apr 23, 2024	Values First Advisors, Inc.	added	149	117,405	214,232	0.13%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	-1,648	132,687	-%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	added	156	167,826	299,831	0.01%
Apr 15, 2024	Medicxi Ventures Management (Jersey) Ltd	unchanged	-	-3,070,290	23,863,200	5.31%
Apr 15, 2024	WEALTH ENHANCEMENT ADVISORY SERVICES, LLC	new	-	116,345	116,345	-%
Apr 11, 2024	Fortitude Family Office, LLC	sold off	-100	-2,011	-	-%
Apr 05, 2024	CWM, LLC	added	8.11	-	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	67.82	6,082,710	15,331,600	-%

Are Funds Buying or Selling AURA?

Are funds buying AURA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AURA

No. of Funds

Unveiling Aura Biosciences, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	citadel advisors llc	7.2%	6	SC 13G/A
Feb 07, 2024	adage capital partners gp, l.l.c.	8.61%	4,225,000	SC 13G/A
Dec 11, 2023	eventide asset management, llc	11.82%	5,802,682	SC 13G/A
Nov 09, 2023	matrix capital management company, lp	14.10%	6,922,870	SC 13D/A
Feb 14, 2023	citadel advisors llc	7.4%	6	SC 13G/A
Feb 14, 2023	eventide asset management, llc	6.3%	2,251,368	SC 13G
Feb 10, 2023	arix bioscience plc	4.1%	1,508,483	SC 13G/A
Feb 09, 2023	adage capital partners gp, l.l.c.	5.76%	2,132,739	SC 13G/A
Jan 20, 2023	chiesi ventures, inc.	3.3%	1,218,803	SC 13G/A
Dec 15, 2022	adage capital partners gp, l.l.c.	5.65%	2,090,665	SC 13G

Recent SEC filings of Aura Biosciences, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 25, 2024	ARS	ARS
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	DEFA14A	DEFA14A
Apr 15, 2024	8-K	Current Report
Apr 15, 2024	PRE 14A	PRE 14A
Apr 05, 2024	EFFECT	EFFECT
Apr 04, 2024	3	Insider Trading
Apr 04, 2024	4	Insider Trading
Mar 27, 2024	S-8	Employee Benefits Plan
Mar 27, 2024	10-K	Annual Report

Peers (Alternatives to Aura Biosciences, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Aura Biosciences, Inc. News

Latest updates

Aura Biosciences, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet											(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4
Assets	41.9%	255	180	193	206	224	143	135	146	160	91.00	22.00
Current Assets	50.6%	232	154	166	179	197	116	128	140	154	83.00	18.00
Cash Equivalents	-26.1%	41.00	56.00	48.00	38.00	122	61.00	54.00	108	149	82.00	17.00
Net PPE	-35.1%	3.00	5.00	5.00	5.00	5.00	5.00	6.00	6.00	5.00	4.00	4.00
Liabilities	4.2%	29.00	28.00	26.00	26.00	28.00	28.00	6.00	5.00	8.00	6.00	3.00
Current Liabilities	13.4%	12.00	11.00	9.00	8.00	10.00	10.00	6.00	5.00	7.00	6.00	3.00
Shareholder's Equity	48.9%	226	152	166	180	196	115	129	141	152	-	-
Retained Earnings	-8.3%	-287	-265	-246	-228	-210	-194	-178	-164	-152	-140	-116
Additional Paid-In Capital	22.9%	513	417	413	409	407	310	308	306	304	9.00	8.00
Shares Outstanding	29.1%	49.00	38.00	38.00	38.00	38.00	29.00	29.00	29.00	29.00	-	0.00
Float	-	-	-	225	-	-	-	280	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)														(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Cashflow From Operations	-12.9%	-17,387	-15,403	-14,645	-16,412	-18,013	-10,760	-10,628	-15,200	-12,086	-8,690	-6,497	-5,137	-	-
Share Based Compensation	12.0%	2,603	2,325	1,931	1,913	1,814	1,717	1,287	1,594	1,297	554	271	185	-	-
Cashflow From Investing	-516.7%	-90,120	21,629	21,407	-66,879	-16,876	17,946	-43,441	-25,498	-819	-573	-662	-71.00	-	-
Cashflow From Financing	5618.6%	92,985	1,626	2,478	201	95,199	104	309	17.00	80,142	-1,116	-256	87,489	-	-

AURA Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating Expenses:
Research and development expenses	$ 65,232	$ 42,238
General and administrative	19,759	18,057
Total operating expenses	84,991	60,295
Total operating loss	(84,991)	(60,295)
Other income (expense):
Interest income, including amortization and accretion income	8,588	1,864
Gain (loss) from disposal of assets	208	(318)
Other income (expense)	(76)	(14)
Total other income (expense)	8,720	1,532
Loss before income taxes	(76,271)	(58,763)
Income tax benefit (provision), net	(137)	0
Net loss	$ (76,408)	$ (58,763)
Net loss per common share - basic	$ (1.93)	$ (1.96)
Net loss per common share - diluted	$ (1.93)	$ (1.96)
Weighted average common stock outstanding - basic	39,620,036	29,937,228
Weighted-average common stock outstanding - diluted	39,620,036	29,937,228
Comprehensive loss:
Net loss	$ (76,408)	$ (58,763)
Other comprehensive items:
Unrealized gain (loss) on marketable securities	611	(72)
Total other comprehensive income (loss)	611	(72)
Total comprehensive loss	$ (75,797)	$ (58,835)

AURA Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 41,063	$ 121,582
Marketable securities	185,087	67,229
Restricted cash and deposits	19	20
Prepaid expenses and other current assets	5,625	7,871
Total current assets	231,794	196,702
Restricted cash and deposits, net of current portion	768	768
Right of use assets - operating lease	18,854	20,671
Other long-term assets	509	423
Property and equipment, net	3,150	5,371
Total Assets	255,075	223,935
Current liabilities:
Accounts payable	1,787	2,921
Short-term operating lease liability	2,687	2,963
Accrued expenses and other current liabilities	7,883	4,573
Total current liabilities	12,357	10,457
Long-term operating lease liability	16,870	17,895
Total Liabilities	29,227	28,352
Commitments and Contingencies (Note 12)
Stockholders' Equity:
Common stock, $0.00001 par value, 150,000,000 authorized at December 31, 2023 and December 31, 2022, and 49,350,788 and 37,771,918 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively
Additional paid-in capital	512,617	406,555
Accumulated deficit	(287,308)	(210,900)
Accumulated other comprehensive loss	539	(72)
Total Stockholders' Equity	225,848	195,583
Total Liabilities, Convertible Preferred Stock, and Stockholders' Equity	$ 255,075	$ 223,935

About Aura Biosciences, Inc.

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for treating tumors of high unmet need in ocular and urologic oncology. It is developing AU-011, a VDC candidate for the treatment of primary choroidal melanoma that is in phase III clinical trial. The company also develops AU-011 for additional ocular oncology indications, including choroidal metastases and is in Phase 2 dose-escalation trial. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.

CEO	Dr. Elisabet de los Pinos Ph.D.
WEBSITE	aurabiosciences.com
INDUSTRY	Biotechnology
EMPLOYEES	70

Aura Biosciences, Inc. Frequently Asked Questions

What is the ticker symbol for Aura Biosciences, Inc.? What does AURA stand for in stocks?

AURA is the stock ticker symbol of Aura Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aura Biosciences, Inc. (AURA)?

As of Fri Apr 26 2024, market cap of Aura Biosciences, Inc. is 357.42 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AURA stock?

You can check AURA's fair value in chart for subscribers.

What is the fair value of AURA stock?

You can check AURA's fair value in chart for subscribers. The fair value of Aura Biosciences, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aura Biosciences, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AURA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aura Biosciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether AURA is over valued or under valued. Whether Aura Biosciences, Inc. is cheap or expensive depends on the assumptions which impact Aura Biosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AURA.